Quantcast

Industry news that matters to you.  Learn more

Archives for October 2012

Lactation Protein Supresses Tumors and Metastasis in Breast Cancer

A protein that is necessary for lactation in mammals inhibits the critical cellular transition that is an early indicator of breast cancer and metastasis, according to research conducted at the University at Buffalo and Princeton University and highlighted as the cover paper in November issue of Nature Cell Biology.

Moffitt Researchers Identify Unique Immune Gene Signature Across Thousands of Patients’ Solid Tumors

Researchers at Moffitt Cancer Center have discovered a unique immune gene signature that can predict the presence of microscopic lymph node-like structures in metastatic melanoma. The presence of these immune structures, the researchers said, appears to be associated with better survival and may indicate the possibility of selecting patients for immunotherapy based solely on the immune-related makeup of their tumors as an approach to personalized medicine.

Agenix to Acquire Diagnostic Device Technology from Tyrian Limited

Agenix Limited (ASX: AGX) today announced it had entered an agreement with Tyrian Diagnostics Limited (ASX: TDX) to license its rapid point-of-care human diagnostic technology in a share exchange transaction.

QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) and Bayer HealthCare today announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular information from each patient’s tumor genome to guide treatment decisions with medications for cancers or other diseases. The parties will also collaborate on the development of novel technologies for patient profiling which may result in innovative research-use-only products for exploratory and translational medicine. Financial details were not disclosed.

Ezose Sciences Forms Alliance with Fast Forward to Discover Biomarkers to Diagnose Multiple Sclerosis

Ezose Sciences Inc. today announced an alliance with Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, to use Ezose’s GlycanMap technology in the discovery of biomarkers to help diagnose multiple sclerosis (MS) and improve disease management.